Journal of Pain & Relief
Open Access

Non-opioid pain management; Neuropathic pain; Chronic pain; Glial cells; Voltage-gated sodium channels; Endocannabinoid system; P2X7 receptor; TRPA1 channel; GPCRs; Gene therapy

Introduction

The landscape of pain management is rapidly evolving, driven by the critical need for non-opioid strategies to address chronic pain effectively. Current treatments often present limitations, which highlights a pressing demand for safer, more potent alternatives to traditional opioids, particularly in light of the ongoing opioid crisis [2].

One area of intense focus is the role of peripheral glial cells, including Schwann cells and satellite glial cells, in the development and maintenance of neuropathic pain. Targeting these specific non-neuronal cells, rather than concentrating solely on neurons, offers a highly promising non-opioid strategy for novel pain management. This approach involves exploring various molecular pathways and potential therapeutic agents that modulate glial cell activity [1].

Advancements in developing non-opioid therapeutic agents for neuropathic pain are particularly crucial, as this condition is often poorly managed by existing treatments. Research delves into a range of molecular targets and mechanisms, such as ion channels, diverse receptors, and glial cell modulators, identifying promising drug candidates while also acknowledging challenges in their clinical translation [4].

Specifically, the therapeutic potential of targeting voltage-gated sodium channels (VGSCs) for pain management is gaining traction. Key channels like Nav1.7, Nav1.8, and Nav1.9 are under scrutiny. The latest developments in selective VGSC blockers indicate their promise as non-opioid analgesics for numerous chronic pain conditions, though challenges and future research avenues remain [3].

Beyond ion channels, the endocannabinoid system's role in modulating pain is extensively reviewed. This system presents significant potential as a therapeutic target for novel analgesics. Discussions include current challenges and opportunities in developing cannabinoid-based drugs, encompassing both plant-derived and synthetic modulators for various pain conditions, with an emphasis on the need for more selective and targeted approaches [5].

The P2X7 receptor is another significant target in chronic pain pathways, largely due to its involvement in neuroinflammation and glial cell activation. Current understanding of P2X7 receptor antagonists suggests their therapeutic potential as novel non-opioid pain relievers. Research continues to offer insights into future directions, despite ongoing challenges in clinical development [6].

Recent breakthroughs in designing and discovering small-molecule modulators that target G protein-coupled receptors (GPCRs) represent a substantial step forward for pain therapy. This work covers various GPCR families implicated in pain pathways, exploring their structural basis for ligand recognition and the development of novel selective agonists and antagonists as potential non-opioid analgesics [7].

A shift in focus towards non-neuronal cells, such as glial cells (astrocytes, microglia, oligodendrocytes) and immune cells, recognizes their crucial role in the pathophysiology of neuropathic pain. Identifying novel therapeutic avenues by modulating these non-neuronal elements proposes new drug candidates and strategies for more effective, non-opioid pain management [8].

The transient receptor potential ankyrin 1 (TRPA1) channel is also highlighted as a key mediator of pain and inflammation, making it an important therapeutic target. An update on the clinical development of TRPA1 antagonists explores their potential in treating various pain conditions, while also outlining the challenges in translating preclinical findings into effective clinical treatments [9].

Finally, recent advances in non-viral gene therapy approaches for chronic pain management are summarized. This area explores various gene delivery systems and therapeutic genes that modulate pain pathways, offering insights into their potential to provide long-lasting pain relief with fewer side effects compared to conventional pharmacotherapies. Both advancements and challenges are thoroughly highlighted in this promising field [10].

Description

Chronic pain, particularly neuropathic pain, presents a significant global health challenge, often characterized by inadequate management through conventional treatments. The current opioid crisis underscores an urgent need for the development of safer and more effective non-opioid analgesic strategies [2, 4]. Researchers are actively exploring novel pharmacological targets and therapeutic approaches to address the limitations of existing pain therapies, aiming to identify emerging classes of analgesics that offer superior outcomes without the risks associated with opioids [2]. This involves a broad re-evaluation of pain mechanisms, moving beyond traditional neuronal models to encompass a more holistic view of pain pathophysiology [8].

A notable shift in pain research is the focus on non-neuronal cells as crucial players in pain development and maintenance. Peripheral glial cells, including Schwann cells and satellite glial cells, are increasingly recognized for their involvement in neuropathic pain [1]. Modulating these glial cells offers a promising non-opioid strategy, exploring specific molecular pathways and potential therapeutic agents distinct from neuron-centric approaches [1]. Similarly, the role of other non-neuronal elements such as astrocytes, microglia, oligodendrocytes, and various immune cells in the pathophysiology of neuropathic pain is being investigated. This line of inquiry aims to identify new therapeutic avenues and drug candidates for more effective pain management [8]. The P2X7 receptor, for instance, is a key target in chronic pain due to its central role in neuroinflammation and glial cell activation, with P2X7 receptor antagonists being explored as novel non-opioid pain relievers despite clinical development hurdles [6].

Molecular targets continue to be a cornerstone of non-opioid analgesic development. Voltage-gated sodium channels (VGSCs), specifically Nav1.7, Nav1.8, and Nav1.9, are areas of intensive study for pain management [3]. Latest advancements in selective VGSC blockers demonstrate their potential as non-opioid treatments for various chronic pain conditions, although challenges and future research directions are still being mapped out [3]. Beyond VGSCs, the transient receptor potential ankyrin 1 (TRPA1) channel stands out as a critical mediator of pain and inflammation. Clinical development of TRPA1 antagonists is underway, with investigations into their efficacy across different pain conditions and the inherent difficulties in translating preclinical successes to human therapies [9]. Furthermore, G protein-coupled receptors (GPCRs) represent a vast family of targets. Breakthroughs in designing and discovering small-molecule modulators for GPCRs are enhancing pain therapy, covering various GPCR families and their structural bases for ligand recognition. This work leads to the development of novel selective agonists and antagonists as potential non-opioid analgesics [7].

The endocannabinoid system offers another compelling avenue for pain management. Its intricate role in pain modulation is being thoroughly reviewed, presenting opportunities for novel analgesics [5]. The development of cannabinoid-based drugs, encompassing both plant-derived compounds and synthetic modulators, for a range of pain conditions is a key area, emphasizing the need for more selective and targeted approaches to maximize therapeutic benefits and minimize side effects [5]. Finally, innovative non-viral gene therapy approaches are emerging as a frontier in chronic pain management. This systematic review explores various gene delivery systems and therapeutic genes designed to modulate pain pathways. The promise of long-lasting pain relief with fewer side effects compared to conventional pharmacotherapies makes gene therapy a particularly exciting area, despite the significant advancements and challenges in its translation [10].

Conclusion

Recent research significantly advances non-opioid strategies for managing chronic and neuropathic pain. A key theme involves shifting focus from solely neuronal targets to include non-neuronal cells, like peripheral glial cells, Schwann cells, satellite glial cells, astrocytes, microglia, and immune cells. Modulating these elements offers promising avenues for effective, non-opioid pain management. Various molecular targets are under investigation, including voltage-gated sodium channels (VGSCs) such as Nav1.7, Nav1.8, and Nav1.9, which show potential as selective blockers. The endocannabinoid system is also explored for its role in pain modulation, with ongoing efforts to develop selective cannabinoid-based drugs. Other significant targets include the P2X7 receptor, recognized for its involvement in neuroinflammation and glial cell activation, and the TRPA1 channel, a key mediator of pain and inflammation, with antagonists currently in clinical development. Breakthroughs in designing small-molecule modulators for G protein-coupled receptors (GPCRs) are also highlighted, focusing on selective agonists and antagonists. Furthermore, non-viral gene therapy approaches are emerging, offering potential for long-lasting pain relief with fewer side effects compared to traditional pharmacotherapies. These diverse strategies collectively aim to provide safer and more effective alternatives to opioids, addressing limitations of current treatments and the ongoing opioid crisis.

References

• Xiaomei M, Yuhan L, Xiaoying W (2023) Targeting Peripheral Glia to Tackle Neuropathic Pain: Recent Advances and Future Perspectives.Cells 12:409.

Indexed at, Google Scholar, Crossref

• Aashish S, Anika S, Amit S (2022) Developments in non-opioid strategies for the management of chronic pain.J Integr Neurosci 21:11.

Indexed at, Google Scholar, Crossref

• Sulaiman A, Christopher W, Katherine AA (2021) Targeting voltage-gated sodium channels for the treatment of pain: recent advances and future directions.Expert Rev Neurother 21:329-346.

Indexed at, Google Scholar, Crossref

• Xiaojing L, Zhiyong W, Yi W (2024) Recent advances in non-opioid therapeutics for neuropathic pain.Drug Discov Today 29:103893.

Indexed at, Google Scholar, Crossref

• Francesca DG, Matteo DC, Giuseppe L (2020) Targeting the cannabinoid system for pain management: current insights and future perspectives.Expert Opin Drug Discov 15:1345-1358.

Indexed at, Google Scholar, Crossref

• Xiaoxiao Y, Yanan Z, Ying C (2023) Targeting the P2X7 receptor for chronic pain treatment: current status and future perspectives.Exp Biol Med (Maywood) 248:788-798.

Indexed at, Google Scholar, Crossref

• Yujing C, Xiaojie Z, Mengmeng L (2022) Advances in the Design and Discovery of Small-Molecule Modulators of GPCRs for Pain Therapy.J Med Chem 65:7073-7104.

Indexed at, Google Scholar, Crossref

• Manuela NCT, Carla MCT, Filipa PCL (2019) Non-neuronal targets in neuropathic pain: from bench to bedside.Expert Opin Drug Discov 14:307-320.

Indexed at, Google Scholar, Crossref

• Michael WWST, Laura CGvdB, Martijn JV (2021) TRPA1 as a therapeutic target for pain: an update on clinical development.Pain Rep 6:e980.

Indexed at, Google Scholar, Crossref

• Xiaoxiao Y, Min Y, Min L (2023) Recent advances in non-viral gene therapy for chronic pain: a systematic review.Exp Biol Med (Maywood) 248:864-874.

Indexed at, Google Scholar, Crossref